



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Box5

Cat. No.:	HY-123071
CAS No.:	1206604-29-6
Molecular Formula:	C ₃₀ H ₅₀ N ₆ O ₁₃ S ₂
Molecular Weight:	766.88
Sequence:	{t-Boc}-Met-Asp-Gly-Cys-Glu-Leu
Sequence Shortening:	{t-Boc}-MDGCEL
Target:	Wnt
Pathway:	Stem Cell/Wnt
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (130.40 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.3040 mL	6.5199 mL	13.0399 mL
5 mM	0.2608 mL	1.3040 mL	2.6080 mL
10 mM	0.1304 mL	0.6520 mL	1.3040 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Box5 is a potent Wnt5a antagonist. Box5 inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca²⁺ release. Box5 inhibits cell migration. Box5 has the potential for the research of melanoma^[1].

IC₅₀ & Target

Wnt5a^[1]

In Vitro

Box5 (100 μM) decreases the expression of rWnt5a (0.1 μg/mL) stimulated p-MARCKS in A2058 cells^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line: A2058 cells

Concentration: 100 μM

Incubation Time:	Overnight
Result:	Decreased the expression of rWnt5a (0.1 µg/mL) stimulated p-MARCKS.

CUSTOMER VALIDATION

- Nano Today. 2024 Apr, 55, 102201.
- Oral Dis. 2024 May 8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jenei V, et al. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19473-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA